tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Keith Tapper, 12 are a BUY (100%).
Analyst Keith Tapper, currently employed at BARCLAYS, carries an average stock price target met ratio of 46.03% that have a potential upside of 64.81% achieved within 173 days.
Keith Tapper’s has documented 24 price targets and ratings displayed on 3 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on TSHA, Taysha Gene Therapies at 23-Jun-2026.
Analyst best performing recommendations are on NGNE (NEUROGENE).
The best stock recommendation documented was for NGNE (NEUROGENE) at 4/14/2025. The price target of $16 was fulfilled within 18 days with a profit of $5.11 (46.92%) receiving and performance score of 26.07.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 15-Dec-2025
$33
$13.05 (65.41%)
$37
13 days ago
(25-Sep-2026)
0/3 (0%)
$12.32 (59.57%)
Buy Since 17-Apr-2025
$34
$14.05 (70.43%)
$36
13 days ago
(25-Sep-2026)
4/6 (66.67%)
$13.32 (64.41%)
144
Buy Since 25-Sep-2025
$31
$11.05 (55.39%)
$38
13 days ago
(25-Sep-2026)
2/6 (33.33%)
$10.32 (49.90%)
574
Buy Since 26-Nov-2019
$33
$13.05 (65.41%)
$36
13 days ago
(25-Sep-2026)
9/25 (36%)
$12.32 (59.57%)
238
Buy Since 28-Feb-2024
$35
$15.05 (75.44%)
$41
13 days ago
(25-Sep-2026)
9/15 (60%)
$14.32 (69.25%)
393
Which stock is Keith Tapper most bullish on?
What Year was the first public recommendation made by Keith Tapper?
